Video

Dr. Dietrich on Future Research Directions in Lung Cancer

Martin Dietrich, MD, PhD, discusses future research directions for the treatment of patients with lung cancer. 

Martin Dietrich, MD, PhD, assistant professor, University of Central Florida, fellow, American College of Physicians, Florida Cancer Specialists & Research Institute, discusses future research directions for the treatment of patients with lung cancer. 

A potentially practice-changing trial is the ongoing phase 3 LAURA study (NCT03521154), which is examining the efficacy and safety of osimertinib (Tagrisso) following chemoradiation in patients with stage III unresectable non­–small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations, according to Dietrich. Based on data from the phase 3 PACIFIC trial (NCT02125461), it is clear that this subset of patients derives some benefit from additional treatment in this setting, Dietrich adds.

Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Binod Dhakal, MD
Sheldon M. Feldman, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.